<SEC-DOCUMENT>0001193125-23-290943.txt : 20231208
<SEC-HEADER>0001193125-23-290943.hdr.sgml : 20231208
<ACCEPTANCE-DATETIME>20231207203627
ACCESSION NUMBER:		0001193125-23-290943
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231207
FILED AS OF DATE:		20231208
DATE AS OF CHANGE:		20231207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231473769

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d608885d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December 7, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d608885dex991.htm">Immutep Receives A$2.6 million R&amp;D Tax Incentive from French Government </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December 7, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d608885dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g608885snap1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Receives
A$2.6&nbsp;million R&amp;D Tax Incentive from French Government </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>7</B><B></B><B>&nbsp;December 2023 &#150;</B>
<U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#147; or &#147;the Company&#148;), a biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy treatments for cancer and autoimmune
diseases, is pleased to announce it has received a &#128;1,595,475 (~ A$2,628,354 ) research and development (R&amp;D) tax incentive payment in cash from the French Government under its Cr&eacute;dit d&#146;Imp&ocirc;t Recherche scheme (CIR). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;Cr&eacute;dit d&#146;Imp&ocirc;t Recherche&#148; (CIR), meaning &#147;Research Tax Credit&#148;, is a French government tax incentive by which
French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep qualifies for the
CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&amp;D activities conducted in the
European Union in the 2022 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government&#146;s R&amp;D tax incentive program in respect of expenditure incurred on eligible R&amp;D activities conducted in Australia.
As previously announced, in October 2023, the company received an A$1.13&nbsp;million cash rebate from the Australian Federal Government&#146;s R&amp;D tax incentive program for the eligible R&amp;D activities conducted in financial year 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited,
</B>Level&nbsp;33, Australia Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">264 George Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g608885snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g608885snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MYR%&/PS6SJ]#KGB4U9'+V]HEYJ,%M:EV$F =PP0>_P" K%*[T.1).:43U8<
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M?K0!UOB36!H>B370 ,I^2,'NQ_PZ_A0!YGH>@WWBR]FFEN6")_K)I,L23V%
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M5BO@(? W_'A=?]=!_*BELQ87X6<'XN_Y&^__ .N@_P#016IUGLL)S"A']T4
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M087X6<MK_P#R'[S_ *Z5E+XCEJ_Q#TV#_CWC_P!T?RKI1Z:V1YIJ'_(SS_\
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M(\KJ%C8YB'<KV)^O6@#R/QE_R-]__O+_ .@B@#V2/_5+]!0 Z@ H * "@ H
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M (GT6SFBN!-$KRSEB9"HW#/ P?88 ^E %@6O^DQ3NVYXXRG3KD@Y_P#'?UH
MDN(!/;2PY($B%2?3(Q0!(B[$51V&* .3U;P);ZMJL]^][+&TI!*J@(& !_2@
M#K5&U0/08H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
;"@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
